Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

Company Overview

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral infections. The company’s research centers on small-molecule therapies designed to interfere with viral replication, with the goal of addressing diseases for which convenient and effective oral treatment options are needed.

Atea’s lead investigational product is bemnifosbuvir, an oral nucleotide polymerase inhibitor developed for the treatment of COVID-19. The company has also pursued antiviral candidates for other infectious diseases, including hepatitis C and dengue. Atea previously entered into a collaboration with Roche to develop bemnifosbuvir for COVID-19, but the collaboration ended in 2022, returning development rights to Atea.

Founded in 2012 and headquartered in Boston, Massachusetts, Atea conducts its research and development activities primarily in the United States. As a clinical-stage company, its products remain subject to clinical testing and regulatory review and are not necessarily approved or commercially available in all targeted markets.

Key Stats

• Today's Range: $5.05 to $5.22
• 50-Day Range: $4.51 to $5.83
• 52-Week Range: $2.81 to $6.45
• Volume: 253,264 shs
• Average Volume: 295,226 shs
• Market Capitalization: $411.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Atea Pharmaceuticals Stock Analysis - MarketRank™

Atea Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 658th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Atea Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Atea Pharmaceuticals has a consensus price target of $7.00, representing about 36.5% upside from its current price of $5.13.

Amount of Analyst Coverage

Atea Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Atea Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Atea Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Atea Pharmaceuticals is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Atea Pharmaceuticals has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.13% of the float of Atea Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Atea Pharmaceuticals has a short interest ratio ("days to cover") of 27.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Atea Pharmaceuticals has recently decreased by 0.44%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Atea Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Atea Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for AVIR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.60% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AVIR
• CIK: 1593899
• Web: www.ateapharma.com
• Phone: 857-284-8891
• Fax: N/A
• Employees: 55
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Atea Pharmaceuticals: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +36.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$158.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.25%
• Return on Assets: -57.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.13
• Quick Ratio: 8.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.53 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 80,210,000
• Free Float: 62,881,000
• Market Cap: $411.48 million
• Optionable: Optionable
• Beta: 0.39